Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

mission pharmacal company - methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv), sodium phosphate, monobasic (unii: 3980jih2sw) (phosphate ion - unii:nk08v8k8hr), phenyl salicylate (unii: 28a37t47qo) (phenyl salicylate - unii:28a37t47qo), methylene blue (unii: t42p99266k) (methylene blue cation - unii:zmz79891zh), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x) - methenamine 81.6 mg - utira ® -c tablets are indicated for the treatment of symptoms of irritative voiding. indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. indicated for the relief of urinary tract symptoms caused by diagnostic procedures. hypersensitivity to any of the ingredients is possible. risk benefits should be carefully considered when the following medical problems exist: cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, and mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis, acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy). a dependence on the use of utira ® -c tablets has not been reported and due to the nature of its ingredients, abuse of utira ® -c tablets is not expected.

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

aquarium muenster pahlsmeier gmbh - ethacridine lactate (unii: v5il571c1t) (ethacridine - unii:wix85m1a6r), methylene blue anhydrous (unii: 8nap7826ub) (methylene blue cation - unii:zmz79891zh), acriflavine hydrochloride (unii: 1s73vw819c) (acriflavine - unii:1t3a50395t), methyl orange (unii: 6b4tc34456) (methyl orange - unii:6b4tc34456) - ethacridine 4 mg in 1 ml - no known contraindications or side effects. should you notice side effects in your ornamental fish, please inform your vet or pharmacist. take unused medical products and unfinished containers of medical products to the designated collection points. date of last revision of package insert 2014-09-10

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

aquarium muenster pahlsmeier gmbh - malachite green oxalate (unii: gy1h9o33vu) (malachite green cation - unii:awt9r95tv1), ethacridine lactate (unii: v5il571c1t) (ethacridine - unii:wix85m1a6r), methylene blue anhydrous (unii: 8nap7826ub) (methylene blue cation - unii:zmz79891zh), gentian violet (unii: j4z741d6o5) (gentian violet cation - unii:3gvj31t6yy) - malachite green oxalate 1.25 mg in 1 ml - none known. should you notice side effects in your ornamental fish, please inform your vet or pharmacist. take unused medical products and unfinished containers of medical products to the designated collection points.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - potassium chloride, quantity: 400 mg/l; sodium lactate, quantity: 3.22 g/l; calcium chloride dihydrate, quantity: 270 mg/l; sodium chloride, quantity: 6 g/l - injection, solution - excipient ingredients: sodium hydroxide; lactic acid; water for injections - is indicated as a source of water and electrolytes. it is also used in patients as a source of bicarbonate in the treatment of mild to moderate metabolic acidosis associated with dehydration or associated with potassium deficiency. these solutions are indicated as methods of intravenous drug delivery, if the drugs are comparable with the solutions. this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code)

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

vilvet pharmaceuticals inc - methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv), phenyl salicylate (unii: 28a37t47qo) (phenyl salicylate - unii:28a37t47qo), sodium phosphate, monobasic, anhydrous (unii: kh7i04hpuu) (phosphate ion - unii:nk08v8k8hr), methylene blue anhydrous (unii: 8nap7826ub) (methylene blue cation - unii:zmz79891zh), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x) - methenamine 118 mg - vilamit mb is indicated for the treatment of symptoms of irritative voiding. indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain which accompany lower urinary tract infections. indicated for the relief of urinary tract symptoms caused by diagnostic procedures. vilamit mb is contraindicated in patients with a hypersensitivity to any of the ingredients. risk-benefit should be considered when the following medical problems exist: cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, and mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis; acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy). a dependence on the use of vilamit mb has not been reported and due to the nature of its ingredients, abuse of vilamit mb is not expected.

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

edwards pharmaceuticals, inc. - methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv), sodium phosphate, monobasic (unii: 3980jih2sw) (sodium cation - unii:lyr4m0nh37), methylene blue (unii: t42p99266k) (methylene blue cation - unii:zmz79891zh), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x) - methenamine 81.6 mg - urogesic-blue™ is indicated for the treatment of symptoms of irritative voiding. indicated for the relief of local symptoms, such as hypermotility which accompany lower urinary tract infections and as antispasmodic. indicated for the relief of urinary tract symptoms caused by diagnostic procedures. urogesic-blue™ is contraindicated in patients with a hypersensitivity to any of the ingredients. risk-benefit should be considered when the following medical problems exist: cardiac disease (especially cardiac arrythmias, congestive heart failure, coronary heart disease, mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis; acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy). a dependence on the use of urogesic-blue™ has not been reported and due to the nature of its ingredients, abuse of urogesic-blue™ is not expected.

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

apace packaging, llc - methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv), sodium phosphate, monobasic, anhydrous (unii: kh7i04hpuu) (sodium cation - unii:lyr4m0nh37), phenyl salicylate (unii: 28a37t47qo) (phenyl salicylate - unii:28a37t47qo), methylene blue (unii: t42p99266k) (methylene blue cation - unii:zmz79891zh), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x) - uroav-b capsules are indicated for the treatment of symptoms of irritative voiding. indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. indicated for the relief of urinary tract symptoms caused by diagnostic procedures. uroav-b capsules are contraindicated in patients with a hypersensitivity to any of the ingredients. risk-benefit should be considered when the following medical problems exist: cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, and mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis; acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy).

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

apace packaging, llc - methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv), sodium phosphate, monobasic, anhydrous (unii: kh7i04hpuu) (sodium cation - unii:lyr4m0nh37), phenyl salicylate (unii: 28a37t47qo) (phenyl salicylate - unii:28a37t47qo), methylene blue (unii: t42p99266k) (methylene blue cation - unii:zmz79891zh), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x) -  uroav-81 tablets is indicated for the treatment of symptoms of irritative voiding. indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. indicated for the relief of urinary tract symptoms caused by diagnostic procedures. uroav-81 tablets is contraindicated in patients with a hypersensitivity to any of the ingredients. risk-benefit should be considered when the following medical problems exist: cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, and mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis; acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy).

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

key therapeutics - methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv), phenyl salicylate (unii: 28a37t47qo) (phenyl salicylate - unii:28a37t47qo), methylene blue (unii: t42p99266k) (methylene blue cation - unii:zmz79891zh), benzoic acid (unii: 8skn0b0mim) (benzoic acid - unii:8skn0b0mim), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i), hyoscyamine (unii: px44xo846x) (hyoscyamine - unii:px44xo846x) - u r i s e d™ is indicated for the relief of discomfort of the lower urinary tract caused by hypermotility resulting from inflammation or diagnostic procedures and in the treatment of cystitis, urethritis, and trigonitis when caused by organisms which maintain or produce an acid urine and are susceptible to formaldehyde. glaucoma, urinary bladder neck obstruction, pyloric or duodenal obstruction, or cardiospasm. hypersensitivity to any of the ingredients. a dependence on the use of u r i s e d™ has not been reported and due to the nature of its ingredients, abuse of u r i s e d™ is not expected.

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

biocomp pharma, inc. - methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv), sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (sodium cation - unii:lyr4m0nh37), phenyl salicylate (unii: 28a37t47qo) (phenyl salicylate - unii:28a37t47qo), methylene blue (unii: t42p99266k) (methylene blue cation - unii:zmz79891zh), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x) - ustell © capsules are indicated for the treatment of symptoms of irritative voiding. indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. indicated for the relief of urinary tract symptoms caused by diagnostic procedures. hypersensitivity to any of the ingredients is possible. risk benefits should be carefully considered when the following medical problems exist: cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, and mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis, acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy). a dependence on the use of ustell © capsules has not been reported and due to the nature of its ingredients, abuse of ustell © capsules is not expected.